Cargando…

Analysis of the Clinical Effects of Sodium Valproate and Levetiracetam in the Treatment of Women with Epilepsy during Pregnancy

OBJECTIVE: To explore the clinical effects of sodium valproate and levetiracetam in the treatment of women with epilepsy during pregnancy. METHODS: The clinical data of 124 women with epilepsy during pregnancy who received monotherapy with antiepileptic drugs (AEDs) in our hospital from September 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Haiqiong, Zhao, Xiaoying, Yu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494592/
https://www.ncbi.nlm.nih.gov/pubmed/34630611
http://dx.doi.org/10.1155/2021/5962200
_version_ 1784579344522280960
author Lv, Haiqiong
Zhao, Xiaoying
Yu, Jian
author_facet Lv, Haiqiong
Zhao, Xiaoying
Yu, Jian
author_sort Lv, Haiqiong
collection PubMed
description OBJECTIVE: To explore the clinical effects of sodium valproate and levetiracetam in the treatment of women with epilepsy during pregnancy. METHODS: The clinical data of 124 women with epilepsy during pregnancy who received monotherapy with antiepileptic drugs (AEDs) in our hospital from September 2017 to January 2020 were retrospectively analyzed. According to the type of medication taken by the patients, they were recorded as the sodium valproate group (the VPA group, n = 56) and the levetiracetam group (the LEV group, n = 68 cases). The effects and the maternal and infant outcomes after treatment were compared between the two groups. The neuron-specific enolase (NSE), cognitive function-related parameters (brain-derived neurotrophic factor (BDNF) and myelin basic protein (MBP)), and related inflammatory factors (tumor necrosis factor- (TNF-) α and interleukin- (IL-) 6) levels were compared between the two groups before and after treatment. RESULTS: After treatment, the total clinical effective rate of the LEV group was 91.18% higher than that of the VPA group 73.21%, and the frequency and duration of seizures were lower than those of the VPA group (P < 0.05). After treatment, the probability of gestational hypertension, depression during pregnancy, low-weight infants, and neonatal deformities in the LEV group was lower than that in the VPA group (P < 0.05). After treatment, the levels of NSE, MBP, TNF-α, and IL-6 in the two groups decreased, and the levels of BDNF increased, and the LEV group changed significantly compared with the VPA group (P < 0.05). CONCLUSION: Compared with sodium valproate monotherapy, levetiracetam is more effective in controlling seizures and improving maternal and infant outcomes in women with epilepsy during pregnancy and can effectively regulate their neurological and cognitive functions and reduce the serum inflammation factor level.
format Online
Article
Text
id pubmed-8494592
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-84945922021-10-07 Analysis of the Clinical Effects of Sodium Valproate and Levetiracetam in the Treatment of Women with Epilepsy during Pregnancy Lv, Haiqiong Zhao, Xiaoying Yu, Jian Evid Based Complement Alternat Med Research Article OBJECTIVE: To explore the clinical effects of sodium valproate and levetiracetam in the treatment of women with epilepsy during pregnancy. METHODS: The clinical data of 124 women with epilepsy during pregnancy who received monotherapy with antiepileptic drugs (AEDs) in our hospital from September 2017 to January 2020 were retrospectively analyzed. According to the type of medication taken by the patients, they were recorded as the sodium valproate group (the VPA group, n = 56) and the levetiracetam group (the LEV group, n = 68 cases). The effects and the maternal and infant outcomes after treatment were compared between the two groups. The neuron-specific enolase (NSE), cognitive function-related parameters (brain-derived neurotrophic factor (BDNF) and myelin basic protein (MBP)), and related inflammatory factors (tumor necrosis factor- (TNF-) α and interleukin- (IL-) 6) levels were compared between the two groups before and after treatment. RESULTS: After treatment, the total clinical effective rate of the LEV group was 91.18% higher than that of the VPA group 73.21%, and the frequency and duration of seizures were lower than those of the VPA group (P < 0.05). After treatment, the probability of gestational hypertension, depression during pregnancy, low-weight infants, and neonatal deformities in the LEV group was lower than that in the VPA group (P < 0.05). After treatment, the levels of NSE, MBP, TNF-α, and IL-6 in the two groups decreased, and the levels of BDNF increased, and the LEV group changed significantly compared with the VPA group (P < 0.05). CONCLUSION: Compared with sodium valproate monotherapy, levetiracetam is more effective in controlling seizures and improving maternal and infant outcomes in women with epilepsy during pregnancy and can effectively regulate their neurological and cognitive functions and reduce the serum inflammation factor level. Hindawi 2021-09-29 /pmc/articles/PMC8494592/ /pubmed/34630611 http://dx.doi.org/10.1155/2021/5962200 Text en Copyright © 2021 Haiqiong Lv et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lv, Haiqiong
Zhao, Xiaoying
Yu, Jian
Analysis of the Clinical Effects of Sodium Valproate and Levetiracetam in the Treatment of Women with Epilepsy during Pregnancy
title Analysis of the Clinical Effects of Sodium Valproate and Levetiracetam in the Treatment of Women with Epilepsy during Pregnancy
title_full Analysis of the Clinical Effects of Sodium Valproate and Levetiracetam in the Treatment of Women with Epilepsy during Pregnancy
title_fullStr Analysis of the Clinical Effects of Sodium Valproate and Levetiracetam in the Treatment of Women with Epilepsy during Pregnancy
title_full_unstemmed Analysis of the Clinical Effects of Sodium Valproate and Levetiracetam in the Treatment of Women with Epilepsy during Pregnancy
title_short Analysis of the Clinical Effects of Sodium Valproate and Levetiracetam in the Treatment of Women with Epilepsy during Pregnancy
title_sort analysis of the clinical effects of sodium valproate and levetiracetam in the treatment of women with epilepsy during pregnancy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494592/
https://www.ncbi.nlm.nih.gov/pubmed/34630611
http://dx.doi.org/10.1155/2021/5962200
work_keys_str_mv AT lvhaiqiong analysisoftheclinicaleffectsofsodiumvalproateandlevetiracetaminthetreatmentofwomenwithepilepsyduringpregnancy
AT zhaoxiaoying analysisoftheclinicaleffectsofsodiumvalproateandlevetiracetaminthetreatmentofwomenwithepilepsyduringpregnancy
AT yujian analysisoftheclinicaleffectsofsodiumvalproateandlevetiracetaminthetreatmentofwomenwithepilepsyduringpregnancy